GDF‐15 is associated with sarcopenia and frailty in acutely admitted older medical patients

• Main Authors: Rikke S. Kamper (Author), Hanne Nygaard (Author), Louis Praeger‐Jahnsen (Author), Anette Ekmann (Author), Sisse Bolm Ditlev (Author), Martin Schultz (Author), Sofie Krarup Hansen (Author), Pernille Hansen (Author), Eckart Pressel (Author), Charlotte Suetta (Author)
• Format: Book
• Published: Wiley, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2190-6009; 2190-5991; 10.1002/jcsm.13513
• Keywords: Biomarker; Frailty; GDF‐15; Old age; Sarcopenia; Senescence; Diseases of the musculoskeletal system; RC925-935; Human anatomy; QM1-695
• Source: Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 4, Pp 1549-1557 (2024)

Abstract Background Growth differentiation factor‐15 (GDF‐15) has been associated with senescence, lower muscle strength, and physical performance in healthy older people. Still, it is not clear whether GDF‐15 can be utilized as a biomarker of sarcopenia and frailty in the early stages of hospitalization. We investigated the association of plasma GDF‐15 with sarcopenia and frailty in older, acutely admitted medical patients. Methods The present study is based on secondary analyses of cross‐sectional data from the Copenhagen PROTECT study, a prospective cohort study including 1071 patients ≥65 years of age admitted to the acute medical ward at Copenhagen University Hospital, Bispebjerg, Denmark. Muscle strength was assessed using handgrip strength, and lean mass was assessed using direct segmental multifrequency bioelectrical impedance analyses and used to clarify the potential presence of sarcopenia defined according to guidelines from the European Working Group on Sarcopenia in Older People. Frailty was evaluated using the Clinical Frailty Scale. Plasma GDF‐15 was measured using electrochemiluminescence assays from Meso Scale Discovery (MSD, Rockville, MD, USA). Results We included 1036 patients with completed blood samples (mean age 78.9 ± 7.8 years, 53% female). The median concentration of GDF‐15 was 2669.3 pg/mL. Systemic GDF‐15 was significantly higher in patients with either sarcopenia (P < 0.01) or frailty (P < 0.001) compared with patients without the conditions. Optimum cut‐off points of GDF‐15 relating to sarcopenia and frailty were 1541 and 2166 pg/mL, respectively. Conclusions Systemic GDF‐15 was higher in acutely admitted older medical patients with sarcopenia and frailty compared with patients without. The present study defined the optimum cut‐off for GDF‐15, related to the presence of sarcopenia and frailty, respectively. When elevated above the derived cutoffs, GDF‐15 was strongly associated with frailty and sarcopenia in both crude and fully adjusted models.